Flagship · Bulletin

Macro rationale

Event-driven, scope-locked patch. Macro digest holds neutral: extension override binds (QQQ +13.17% >200d) lifting cash target to 17% with an escalated 25% ceiling, but the base 5-15% floor is unmoved and the book sits at ~5% cash (band floor) — within band, no clip. Credit (HY OAS 2.69 vs 90d SMA 2.87) and VIX 16.5 confirm the complacency gap is intact. The named new signal is Iran's dual Hormuz+Bab al-Mandeb threat (~30% of seaborne oil/gas) — a high-severity geopolitical tail that VALIDATES the energy/commodity + gold hedge legs (CCJ, SCCO, NEM) and the defense sleeve rather than reversing any thesis. stale_policy=YES forbids adds, so I cannot lean into the +5pp energy/defense tilt the digest recommends — this is a hold-and-confirm, not a rotation. The MP trigger (China export blacklist, −13.4%) is a real headwind on the magnet-ramp leg but not a durability/flow break: the DoD price-floor + offtake funder is intact. Neutral stands.

Thesis

Scope-locked event-driven patch, trigger = MP China export blacklist. Only [MP, CCJ, GEV, SCCO, NEM] are eligible for weight changes; all other names hold verbatim at delta 0. stale_policy=YES blocks any open/add. My read: the trigger is a headwind, not a break. MP's core thesis is the DoD-backstopped floor (`$400M preferred + $150M loan + 10-yr $110/kg NdPr price floor + 10-yr magnet offtake`), which is intact — the blacklist pressures the magnet-ramp ambition leg but the government price floor caps economic downside. MP is already right-sized twice and sits at 2.71% live / 5.01% target; a −13.4% price move is not a §6.5 sell trigger. The energy hedges (CCJ uranium, SCCO copper, NEM gold, GEV grid) are VALIDATED by the Hormuz/Bab al-Mandeb escalation — a hold-and-lean signal — but stale_policy forbids the add, and their score drift is explicitly not a trim trigger (thematic tailwind intact per pillar digests). NEM (score 89, TD Cowen upgrade) is the standout hedge, held. Zero discretionary changes — the disciplined, expected quiet-run outcome. PSN (score 50, broken) remains queued for closure at the next full deep run where a replacement open is permitted; closing it alone breaches the 18-position floor and stale_policy blocks the fix.

Reflection

MP blacklist is a magnet-leg headwind on an intact DoD-backstopped floor, not a thesis break; Hormuz escalation re-validates the energy/gold hedges. Hold-and-confirm.

New wrinkle on MP this run beyond the June blacklist: the USA Rare Earth SEC filing (93.8M shares, 35.2% of float) plus competitor legal action compound execution uncertainty on the magnet ramp. But none of this touches the DoD price-floor/offtake, which is the actual funder — the position is already tiny (2.71% live) and twice-trimmed, so trimming again on price weakness would be exactly the churn I keep flagging. The recurring structural trap persists: PSN is genuinely broken (50) but scope-lock + stale_policy + the 18-position floor keep it carried on a technicality. Must resolve at next fu

Positions (15)

• MUMicron Technologycompute

  hold3.55%79
  flow steadyconf

  Funder

  US HBM3E/HBM4 supplier in a capacity-disciplined memory cycle; 84.6% GM, FCF+. 16 Strategic Customer Agreements covering ~20% DRAM / ~1/3 NAND through 2030 (~$100B contracted); ~$725B 2026 hyperscaler capex line funds HBM demand.

  Unwind

  DRAM/NAND spot-price collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; SCA contract-book erosion.

  Catalyst

  Next quarterly print — HBM bookings + DRAM spot-price floor confirmation.

  Scenarios · 12mo targets

  $155.00 base

  $190.00 bull — HBM4 ramp + memory shortage extends through decade; SCA book expands and pricing holds.

  $100.00 bear — Memory cycle rolls over, HBM oversupply, hyperscaler capex trims DRAM demand.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold7.79%83
  flow steadyconf

  Funder

  World-leading foundry with effective monopoly at <=3nm. Every meaningful AI accelerator routes through TSMC.

  Unwind

  Gross margin sustained <50% for two consecutive quarters.

  Catalyst

  preserved

• NVDANVIDIAcompute

  hold2.90%72
  flow steadyconf

  Funder

  AI accelerator monopoly with CUDA software moat. Data-center compute platform leader of this cycle.

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters.

  Catalyst

  preserved

• ASMLASML Holdingcompute

  hold3.69%64
  flow steadyconf

  Funder

  EUV and High-NA monopoly. Only viable path to leading-edge logic; structural pricing power.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters.

  Catalyst

  preserved

• AVGOBroadcomcompute

  hold2.26%62
  flow steadyconf

  Funder

  Custom silicon for hyperscalers + networking + VMware moat. Diversified AI-infrastructure leverage.

  Unwind

  AI custom-chip revenue stalls below $25B annual run-rate.

  Catalyst

  preserved

• ANETArista Networkscompute

  hold1.93%67
  flow steadyconf

  Funder

  Arista Networks — durable hyperscaler networking franchise; market-share gainer since 2004, ~65% gross margin, net cash, single-image EOS software moat, Ullal-led capital discipline. Flow: Microsoft & Meta named as its largest customers funding 800G/AI back-end switching under the ~$725B 2026 hyperscaler capex wave. Replaces broken MRCY with an established compounder.

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating.

  Catalyst

  preserved

• FNcompute

  hold1.38%63
  flow steadyconf

  Funder

  Brief §7.1 explicit mid-cap candidate. AWS hyperscaler is dominant customer driving 35.9% YoY revenue growth prior Q; Q3 FY26 total revenue $872M (+19% YoY). 800G/1.6T optical transceiver demand from Nvidia/AMD GPU clusters. Extracts hyperscaler CapEx wave without absorbing component-inflation tax that hits hyperscalers and model-builders. $24.6B mcap — mid-cap displacement.

  Unwind

  Datacom segment sequential decline >5% or gross margin compresses below 11%.

  Catalyst

  preserved

• KTOSKratos Defensedefense

  hold11.14%
  flow steadyconf

  Funder

  DoD MACH-TB 2.0 IDIQ prime: $1.45B ceiling 5-year (signed Jan 6 2025); DoD Industrial Base Project Helios hypersonic materials center $68.3M single-award (Oct 2025); USMC XQ-58A Valkyrie MUX TACAIR $34.8M mod (Jan 2025); C5ISR hardware $30M (Dec 2025); aviation training $65M (Feb 2026). Pure-play on Replicator/hypersonic flow per brief §5.3.

  Unwind

  preserved out-of-scope

  Catalyst

  preserved

• HEIHEICOdefense

  hold11.44%68
  flow steadyconf

  Funder

  Defense aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR sustained. Acquisition tape adding $1B+ rev annually. Wencor integration accretive. Score 68 on watchlist; NDAA mandatory funding + commercial aerospace MRO cycle dual-tailwind.

  Unwind

  Organic growth decelerates below 6% with margin compression.

  Catalyst

  preserved

• PSNdefense

  hold3.60%50
  flow steadyconf

  Funder

  Parsons — MDA SHIELD IDIQ awardee, $151B ceiling (Dec 2025); DTRA cyber-ops IDIQ $137M; USAF MATOC $15B; Navy WEXMAC TITUS 2.1 IDIQ $10B; $100M DoD munitions contract — all prime awards per Parsons IR. Iran strikes on Kuwait/Bahrain directly bid missile-defense/C-UAS integration. Mid-cap defense prime, flow_score 79.

  Unwind

  Book-to-bill falls below 1.0 two consecutive quarters

  Catalyst

  preserved

• LLYEli Lillybiology

  hold5.03%70
  flow steadyconf

  Funder

  Durable franchise: premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise + retatrutide Ph3 (~70lb loss) extends a multi-decade runway, deep margins, strong capital return. Profitable and cash-generative — NOT the rate-vise cash-burner the brief warns off. Flow/timing: Norway GPFG/large AM holders; GLP-1 TAM expansion; Zealand rival failure cleared the runway. Re-establishing after a mechan

  Unwind

  Tirzepatide US script share falls >5pts to NVO over two quarters.

  Catalyst

  preserved

• VRTXVertex Pharmaceuticalsbiology

  hold2.31%76
  flow steadyconf

  Funder

  Durable biology compounder: cystic-fibrosis monopoly (Trikafta) cash engine, self-funded, high margins, fortress balance sheet — a genuine 20-30yr franchise. Tailwind: Casgevy commercializing across 12+ jurisdictions with the Medicare Cell & Gene Therapy Access Model (a named federal reimbursement flow); Journavx (suzetrigine) non-opioid pain launch; Crinetics deal adds endocrine optionality; Norw

  Unwind

  CF franchise erodes faster than non-CF revenue can replace.

  Catalyst

  preserved

• ARGXargenxbiology

  hold3.01%70
  flow steadyconf

  Funder

  argenx — Vyvgart/Vyvgart Hytrulo (efgartigimod) autoimmune franchise; self-funded commercial-stage biotech, high-margin, net cash, a durable 20-30yr FcRn franchise. Named flow: FDA expanded gMG approval to all serotypes incl. seronegative (5/28, ~18% TAM expansion); CIDP approval + MMN/SjD label expansions inflecting; peak-sales trajectory $6B→$16B by 2036; GPFG/large AM holders. Belgian ADR adds

  Unwind

  preserved out-of-scope

  Catalyst

  preserved

• SCCOSouthern Copperenergy

  hold8.70%63
• NEMNewmont Corporationenergy

  hold6.27%89

Warnings

• §2 cap applied: MU
• tilt_truncated: energy tilt +5pp ignored (pillar empty)
• tilt_truncated: defense tilt +5pp ignored (pillar empty)
• tilt_truncated: biology tilt -2pp ignored (pillar empty)
• Non-US share 0.0% < 15% floor (§2/§3)
• position_count: 15 < 18 after mechanical closes (§2 floor) — book under-populated; strategist must open replacements next run

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —
3. Turn 3ConvictionGuard (§6.5d)

   —
4. Turn 4ConvictionGuard (§6.5d)

   —
5. Turn 5ConvictionGuard (§6.5d)

   —
6. Turn 6ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.